Shark Tank Hungary: Algae-Based Brain Health Capsule Faces Packaging Debate & Investment Loss

The Hungarian version of Shark Tank, Cápák között, saw an intriguing pitch this weekend from Daoda Zoltán and Dr. Kutasi József of Albitech, a biotechnology firm developing an algae-based supplement aimed at slowing the progression of neurodegenerative diseases. The pair sought a 40 million forint (approximately $108,000 USD as of March 2, 2026) investment in exchange for a 15% stake in their company, centered around their product, Memo-Biom.

Albitech’s foundation lies in research initially focused on agricultural applications of algae. The founders discovered potential benefits for human health, specifically in addressing neurological conditions. Their Memo-Biom capsules utilize active ingredients derived from algae, intended to positively impact the human nervous system. This pivot from farm to pharmacy is a compelling narrative and one that immediately sparked debate among the “sharks.”

Packaging and Perception: A Point of Contention

The initial critique came from Balogh Levente, who immediately zeroed in on the product’s packaging. “You can’t sell this… Packaging is very important. This is a very expensive product, but it’s also very good, and the packaging needs to reflect that,” he stated. This highlights a common tension in the supplement market: balancing perceived value with cost and accessibility. A premium product often requires premium presentation to justify its price point.

However, Bojinka Miklós offered a contrasting perspective, arguing that elaborate packaging isn’t always necessary. “I don’t agree with Levi that we should spend a lot of money on additional packaging. Most vitamin consumers eat this every day, and not because the packaging was gorgeous. But because their nutritionist, professor, or doctor recommended the active ingredient,” he countered. This speaks to the power of professional endorsements and the importance of efficacy over aesthetics for a certain segment of the market. Pénzcentrum reported on the deal, noting the strong disagreement between the investors.

The debate escalated with a warning from Balogh Levente about potential challenges from the pharmaceutical industry. “Professor, there’s a small problem! The pharmaceutical lobby will push you into pharmacies so hard that you won’t even know where you were,” he quipped, injecting a dose of realism into the discussion. This underscores the regulatory hurdles and competitive landscape that Albitech would likely face as they attempt to scale their business.

Investment Landscape and Ownership Structure

Despite initial interest from Balogh Levente and Balogh Petya, the investment ultimately fell through due to the existing ownership structure of Albitech. The company already had a majority owner, preventing the sharks from securing a significant enough stake to justify their investment. However, Balogh Levente expressed openness to revisiting the deal if the ownership structure were to change, leaving the door open for future collaboration.

This situation is not uncommon in Shark Tank-style pitches. Control and equity are often the sticking points in negotiations. Investors seek sufficient ownership to influence the direction of the company and ensure a return on their investment, while founders are understandably reluctant to relinquish too much control.

The Broader Context of Algae-Based Supplements

Albitech’s focus on algae as a source of neuroprotective compounds aligns with a growing trend in the wellness industry. Algae, particularly certain strains like spirulina and chlorella, are increasingly recognized for their nutritional density and potential health benefits. These benefits range from antioxidant properties to supporting immune function. RTL.hu detailed the company’s origins in agricultural research and their subsequent discovery of the algae’s potential for human health.

The market for nootropics – supplements designed to enhance cognitive function – is also experiencing significant growth. Consumers are increasingly seeking natural and preventative solutions to support brain health and combat age-related cognitive decline. Albitech’s Memo-Biom aims to tap into this demand by offering a scientifically-backed, algae-derived supplement.

What’s Next for Albitech?

While the immediate investment opportunity with the Cápák között sharks didn’t materialize, the exposure from the show could prove invaluable for Albitech. The publicity generated by the pitch will likely increase brand awareness and potentially attract other investors. The company’s next steps will likely focus on refining their product, strengthening their intellectual property, and exploring alternative funding options. A potential restructuring of ownership to attract further investment remains a key possibility, as indicated by Balogh Levente’s conditional offer.

The company’s success will hinge on demonstrating the efficacy of Memo-Biom through rigorous clinical trials and building a strong brand reputation. Navigating the complex regulatory landscape of the supplement industry will also be crucial. The founders’ background in agricultural research and biotechnology provides a solid foundation, but they will need to leverage expertise in marketing, sales, and regulatory affairs to achieve their long-term goals.

The pitch also highlights the ongoing interest in innovative solutions for neurodegenerative diseases. As the global population ages, the demand for effective treatments and preventative measures will only continue to grow. Albitech’s approach, leveraging the power of algae, represents a promising avenue for future research and development in this critical area of healthcare. RTL Pont Hu’s Facebook page also covered the pitch, indicating the broad appeal of the story.